{
    "clinical_study": {
        "@rank": "141081", 
        "arm_group": {
            "arm_group_label": "Treatment (ipilimumab)", 
            "arm_group_type": "Experimental", 
            "description": "Patients receive ipilimumab IV over 90 minutes. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients achieving objective response or stable disease continue to receive maintenance therapy comprising ipilimumab IV over 90 minutes once every 12 weeks. Maintenance treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity."
        }, 
        "brief_summary": {
            "textblock": "This phase II trial studies how well giving ipilimumab works in treating patients with human\n      papilloma virus (HPV)-related cervical cancer that has come back or that has spread to other\n      areas of the body. Monoclonal antibodies, such as ipilimumab, can find tumor cells and help\n      kill them or carry tumor-killing substances to them."
        }, 
        "brief_title": "Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical Cancer", 
        "condition": [
            "Cervical Adenocarcinoma", 
            "Cervical Squamous Cell Carcinoma", 
            "Human Papilloma Virus Infection", 
            "Recurrent Cervical Cancer", 
            "Stage IVA Cervical Cancer", 
            "Stage IVB Cervical Cancer"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Adenocarcinoma", 
                "Carcinoma", 
                "Carcinoma, Squamous Cell", 
                "Uterine Cervical Neoplasms", 
                "Papilloma", 
                "Virus Diseases", 
                "Warts", 
                "Papillomavirus Infections"
            ]
        }, 
        "detailed_description": {
            "textblock": "PRIMARY OBJECTIVES:\n\n      I. To assess the safety of ipilimumab in eligible patients with recurrent or metastatic\n      cervical cancer.\n\n      II. To assess the antitumor activity of ipilimumab in eligible patients with recurrent or\n      metastatic cervical cancer via assessment of objective response rates (ORR).\n\n      SECONDARY OBJECTIVES:\n\n      I. To assess the antitumor activity of ipilimumab through secondary endpoints including of\n      disease stabilization and progression free survival (PFS).\n\n      II. Assessment of antitumor activity of ipilimumab using immune-related response criteria\n      (irRC) III. Assessment of the predictive value of baseline C-reactive protein. IV. Assess\n      the biologic responses of exposure to ipilimumab via correlative studies involving analysis\n      of lymphocyte subsets and assessment of cervical cancer-antigen specific T cells anti-tumor\n      response.\n\n      V. Evaluation of archival tissue with regard to markers of immune population in correlation\n      with clinical stage and response to treatment.\n\n      OUTLINE:\n\n      Patients receive ipilimumab intravenously (IV) over 90 minutes. Treatment repeats every 21\n      days for 4 courses in the absence of disease progression or unacceptable toxicity. Patients\n      achieving objective response or stable disease continue to receive maintenance therapy\n      comprising ipilimumab IV over 90 minutes once every 12 weeks. Maintenance treatment repeats\n      every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.\n\n      After completion of study treatment, patients are followed up for 1 year."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients must have histologically or cytologically confirmed metastatic or recurrent\n             HPV-related cervical cancer of squamous, adenocarcinoma or mixed histology type not\n             suited to definitive localized therapy\n\n          -  Patients must have measurable disease, defined as at least one lesion that can be\n             accurately measured in at least one dimension (longest diameter to be recorded for\n             non-nodal lesions and short axis for nodal lesions) as > 20 mm with conventional\n             techniques or as > 10 mm with spiral computed tomography (CT) scan, magnetic\n             resonance imaging (MRI), or calipers by clinical exam\n\n          -  Previous therapy:\n\n               -  Patients may have undergone surgery and/or received definitive radiation or\n                  chemo-radiation for localized disease in the past\n\n               -  Radiation treatment must have been completed >= 3 months prior to enrollment\n\n               -  Patients must have been exposed to platinum chemotherapy either as part of\n                  definitive chemo-radiation OR as first line systemic treatment for metastatic\n                  disease\n\n               -  Patients MAY have received up to two prior lines of systemic chemotherapy for\n                  metastatic or recurrent disease; patients with metastatic disease at first\n                  presentation MUST have received one platinum based line of chemotherapy\n\n               -  All chemotherapy must have been completed >= 4 weeks prior to enrollment with\n                  radiologic evidence of radiological disease progression\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-1\n\n          -  Life expectancy of greater than 3 months\n\n          -  Leukocytes >= 3.0 x 10^9/L\n\n          -  Absolute neutrophil count >= 1.5 x 10^9/L\n\n          -  Platelets >= 100 x 10^9/L\n\n          -  Total bilirubin within normal institutional limits (except in Gilbert's syndrome)\n\n          -  Thyroid stimulating hormone (TSH) within normal institutional limits\n\n          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase\n             [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])\n             =< 2.5 X institutional upper limit of normal\n\n          -  Creatinine < 1.25 x upper limit of normal (ULN) OR creatinine clearance >=\n             50mL/min/1.73 m^2 as calculated by the Cockroft and Gault formula\n\n          -  All radiology studies must be performed =< 3 weeks prior to the start of therapy\n\n          -  Subjects with treated and asymptomatic brain metastases are eligible; patients that\n             received palliative radiation (for brain metastases) are eligible if they do not\n             require maintenance steroid treatment, have been asymptomatic for at least 2 weeks\n             following cessation of steroid therapy, and last received radiation at least 4 weeks\n             prior to start of therapy\n\n          -  Ability to understand and willing to sign a written informed consent document\n\n          -  Ongoing prior toxicities related to previous treatments must be recovered to < grade\n             1 at the time of registration (with the exception of alopecia or skin depigmentation)\n\n          -  Patients are willing to undergo tumor biopsy pre-treatment (7 days prior to\n             registration) and post-treatment (within the first week of cycle 2 onset); patients\n             who consent but have tumor that is not amenable to safe biopsy will be allowed to\n             enter the trial/continue therapy as per protocol if this has been addressed and\n             permission is granted from the lead consortium principal investigator (PI) prior to\n             registration continuation of treatment\n\n        Exclusion Criteria:\n\n          -  Patients who have had chemotherapy < 4 weeks prior to enrollment (< 6 weeks for\n             nitrosoureas or mitomycin C) or who had radiation < 3 months prior to enrollment or\n             those who have not recovered (< grade 1) from adverse events related to previous\n             treatments are excluded\n\n          -  Patients with a history of prior treatment with Ipilimumab or other cytotoxic\n             T-lymphocyte antigen 4 (CTLA4) agonists or antagonists, anti-programmed death 1 (PD\n             1) antibody, cluster of differentiation (CD)137 agonist or other immune activating\n             therapy such as anti-CD 40 antibody are excluded\n\n          -  Patients who are receiving any other investigational agents\n\n          -  Autoimmune disease: Patients with a history of inflammatory bowel disease, including\n             ulcerative colitis and Crohn's disease, are excluded from this study, as are patients\n             with a history of symptomatic disease (e.g., rheumatoid arthritis, systemic\n             progressive sclerosis [scleroderma], systemic lupus erythematosus, autoimmune\n             vasculitis [e.g., Wegener's granulomatosis]); central nervous system (CNS) or motor\n             neuropathy considered of autoimmune origin (e.g. Guillain-Barre syndrome and\n             Myasthenia Gravis, multiple sclerosis\n\n          -  Patients requiring immunosuppressive agents, unless required for treating potential\n             immune related adverse effects; steroids at their lowest effective dose in patients\n             with radiated brain metastases is permitted\n\n          -  Patients with known immune impairment who may be unable to respond to anti-CTLA 4\n             antibody\n\n          -  Any other prior malignancy from which the patient has been disease free for less than\n             3 years, with the exception of adequately treated and cured basal or squamous cell\n             skin cancer, superficial bladder cancer, carcinoma in situ of any site or any other\n             cancer\n\n          -  History of allergic reactions attributed to compounds of similar chemical or biologic\n             composition to ipilimumab\n\n          -  Patients requiring systemic steroids are excluded, as these drugs may interfere with\n             the activity of ipilimumab if administered at the time of the first ipilimumab dose;\n             narcotics should be used with caution as they may mask the signs and symptoms of\n             serious gastrointestinal immune-related adverse events (irAEs) including intestinal\n             perforation\n\n          -  Uncontrolled intercurrent illness including, but not limited to, ongoing or active\n             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac\n             arrhythmia, or psychiatric illness/social situations that would limit compliance with\n             study requirements; patients with chronic hepatitis B or hepatitis C infections\n             should be excluded because of potential effects on immune function and/ or drug\n             interactions\n\n          -  Pregnant women are excluded from this study because ipilimumab is an agent with the\n             potential for teratogenic or abortifacient effects; because there is an unknown but\n             potential risk for adverse events in nursing infants secondary to treatment of the\n             mother with ipilimumab, breastfeeding should be discontinued if the mother is treated\n             with ipilimumab\n\n          -  Patients with active or chronic infection with human immunodeficiency virus (HIV) who\n             have raised viral loads or uncontrolled disease are ineligible because of the\n             potential for anticipated and unknown adverse immune related effects secondary to\n             treatment with ipilimumab; those patients however who exhibit minimal viral loads\n             with good control whilst on stable anti-viral regimen may be considered if they meet\n             all other eligibility criteria"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 21, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693783", 
            "org_study_id": "NCI-2012-02877", 
            "secondary_id": [
                "NCI-2012-02877", 
                "PHL-085", 
                "9209", 
                "N01CM00071", 
                "N01CM00038", 
                "N01CM00032"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Treatment (ipilimumab)", 
                "description": "Given IV", 
                "intervention_name": "ipilimumab", 
                "intervention_type": "Biological", 
                "other_name": [
                    "anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody", 
                    "MDX-010", 
                    "MDX-CTLA-4", 
                    "monoclonal antibody CTLA-4"
                ]
            }, 
            {
                "arm_group_label": "Treatment (ipilimumab)", 
                "description": "Correlative studies", 
                "intervention_name": "laboratory biomarker analysis", 
                "intervention_type": "Other"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antibodies, Monoclonal", 
                "Cytotoxic T-lymphocyte antigen 4"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 30, 2014", 
        "location": [
            {
                "contact": {
                    "email": "mcristea@coh.org", 
                    "last_name": "Mihaela C. Cristea", 
                    "phone": "626-256-4673"
                }, 
                "facility": {
                    "address": {
                        "city": "Duarte", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91010"
                    }, 
                    "name": "City of Hope"
                }, 
                "investigator": {
                    "last_name": "Mihaela C. Cristea", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lroman@usc.edu", 
                    "last_name": "Lynda D. Roman", 
                    "phone": "323-865-0451"
                }, 
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "90033"
                    }, 
                    "name": "University of Southern California/Norris Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lynda D. Roman", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "edwin.alvarez@ucdmc.ucdavis.edu", 
                    "last_name": "Edwin A. Alvarez", 
                    "phone": "916-734-6900"
                }, 
                "facility": {
                    "address": {
                        "city": "Sacramento", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "95817"
                    }, 
                    "name": "University of California at Davis Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Edwin A. Alvarez", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Skoehler@cohmg.com", 
                    "last_name": "Stephen C. Koehler", 
                    "phone": "626-396-2900"
                }, 
                "facility": {
                    "address": {
                        "city": "South Pasadena", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "91030"
                    }, 
                    "name": "City of Hope South Pasadena"
                }, 
                "investigator": {
                    "last_name": "Stephen C. Koehler", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "gfleming@medicine.bsd.uchicago.edu", 
                    "last_name": "Gini F. Fleming", 
                    "phone": "773-702-6712"
                }, 
                "facility": {
                    "address": {
                        "city": "Chicago", 
                        "country": "United States", 
                        "state": "Illinois", 
                        "zip": "60637"
                    }, 
                    "name": "University of Chicago"
                }, 
                "investigator": {
                    "last_name": "Gini F. Fleming", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "lainie.Martin@fccc.edu", 
                    "last_name": "Lainie P. Martin", 
                    "phone": "215-728-3889"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "19111"
                    }, 
                    "name": "Fox Chase Cancer Center"
                }, 
                "investigator": {
                    "last_name": "Lainie P. Martin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "Prafull.Ghatage@albertahealthservices.ca", 
                    "last_name": "Prafull Ghatage", 
                    "phone": "403-521-3721"
                }, 
                "facility": {
                    "address": {
                        "city": "Calgary", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T2N 4N2"
                    }, 
                    "name": "Tom Baker Cancer Centre"
                }, 
                "investigator": {
                    "last_name": "Prafull Ghatage", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "katia.tonkin@albertahealthservices.ca", 
                    "last_name": "Katia S. Tonkin", 
                    "phone": "780-432-8514"
                }, 
                "facility": {
                    "address": {
                        "city": "Edmonton", 
                        "country": "Canada", 
                        "state": "Alberta", 
                        "zip": "T6G 1Z2"
                    }, 
                    "name": "Cross Cancer Institute"
                }, 
                "investigator": {
                    "last_name": "Katia S. Tonkin", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "atinker@bccancer.bc.ca", 
                    "last_name": "Anna Tinker", 
                    "phone": "604-877-6000"
                }, 
                "facility": {
                    "address": {
                        "city": "Vancouver", 
                        "country": "Canada", 
                        "state": "British Columbia", 
                        "zip": "V5Z 1L3"
                    }, 
                    "name": "BC Cancer Research Centre"
                }, 
                "investigator": {
                    "last_name": "Anna Tinker", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "hal.hirte@jcc.hhsc.ca", 
                    "last_name": "Holger W. Hirte", 
                    "phone": "905-387-9495"
                }, 
                "facility": {
                    "address": {
                        "city": "Hamilton", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "L8V 5C2"
                    }, 
                    "name": "Juravinski Cancer Centre at Hamilton Health Sciences"
                }, 
                "investigator": {
                    "last_name": "Holger W. Hirte", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jim.biagi@krcc.on.ca", 
                    "last_name": "James J. Biagi", 
                    "phone": "613-544-2630"
                }, 
                "facility": {
                    "address": {
                        "city": "Kingston", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K7L 5P9"
                    }, 
                    "name": "Cancer Centre of Southeastern Ontario at Kingston General Hospital"
                }, 
                "investigator": {
                    "last_name": "James J. Biagi", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "stephen.welch@lhsc.on.ca", 
                    "last_name": "Stephen A. Welch", 
                    "phone": "519-685-8640"
                }, 
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "N6A 4L6"
                    }, 
                    "name": "London Regional Cancer Program"
                }, 
                "investigator": {
                    "last_name": "Stephen A. Welch", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "jweberpals@ottawahospital.on.ca", 
                    "last_name": "Johanne I. Weberpals", 
                    "phone": "613-737-8899ext76462"
                }, 
                "facility": {
                    "address": {
                        "city": "Ottawa", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "K1H 8L6"
                    }, 
                    "name": "Ottawa General Hospital"
                }, 
                "investigator": {
                    "last_name": "Johanne I. Weberpals", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "amit.oza@uhn.ca", 
                    "last_name": "Amit M. Oza", 
                    "phone": "416-946-2818"
                }, 
                "facility": {
                    "address": {
                        "city": "Toronto", 
                        "country": "Canada", 
                        "state": "Ontario", 
                        "zip": "M5G 2M9"
                    }, 
                    "name": "University Health Network-Princess Margaret Hospital"
                }, 
                "investigator": {
                    "last_name": "Amit M. Oza", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Canada"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 2 Study of Ipilimumab in Women With Metastatic or Recurrent HPV-Related Cervical Carcinoma of Either Squamous Cell or Adenocarcinoma Histologies", 
        "overall_official": {
            "affiliation": "Princess Margaret Hospital Phase 2 Consortium", 
            "last_name": "Amit Oza", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest.", 
            "measure": "Frequency and severity of adverse events, graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) v4.0", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 1 year"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693783"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Computed using the Kaplan-Meier method.", 
                "measure": "Progression free survival (PFS)", 
                "safety_issue": "No", 
                "time_frame": "Time from start of treatment to time of progression or death, whichever occurs first, assessed up to 1 year"
            }, 
            {
                "description": "Summary statistics, such as mean, median, counts and proportion, will be used.", 
                "measure": "Antitumor activity (partial response [PR], complete response [CR], and stable disease [SD]) using immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) v1.1", 
                "safety_issue": "No", 
                "time_frame": "Up to 1 year"
            }, 
            {
                "measure": "Predictive value of baseline C-reactive protein", 
                "safety_issue": "No", 
                "time_frame": "Up to week 3 of course 4"
            }
        ], 
        "source": "National Cancer Institute (NCI)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Cancer Institute (NCI)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}